ITGAE KO cell line available to order. KO validated by Next Generation Sequencing. Free of charge wild type control provided. Knockout achieved by CRISPR/Cas9 X = 1 bp insertion after Ile386 of the WT protein
Frameshift: 100%.
Images
Key facts
- Cell type
- HeLa
- Species or organism
- Human
- Tissue
- Cervix
- Form
- Liquid
- Knockout validation
- Next Generation Sequencing
- Mutation description
- Knockout achieved by CRISPR/Cas9 X = 1 bp insertion after Ile386 of the WT protein Frameshift: 100%
Alternative names
A530055J10, Antigen CD103, CD 103, CD103 antigen, HML-1 antigen, Human mucosal lymphocyte antigen 1, Human mucosal lymphocyte antigen 1, alpha subunit, Huminae, ITAE_HUMAN, Integrin alpha E, Integrin alpha E light chain, Integrin alpha E, epithelial-associated, Integrin alpha E1, Integrin alpha M290, Integrin alpha-E heavy chain, Integrin alpha-IEL, Integrin, alpha E (antigen CD103, human mucosal lymphocyte antigen 1; alpha polypeptide), Itgae, MGC141996, MGC183601, Mucosal lymphocyte 1 antigen, Mucosal lymphocyte antigen 1, aM290, alpha-E1, alpha-M290
Recommended products
ITGAE KO cell line available to order. KO validated by Next Generation Sequencing. Free of charge wild type control provided. Knockout achieved by CRISPR/Cas9 X = 1 bp insertion after Ile386 of the WT protein
Frameshift: 100%.
Key facts
- Cell type
- HeLa
- Species or organism
- Human
- Tissue
- Cervix
- Form
- Liquid
- Knockout validation
- Next Generation Sequencing
- Mutation description
- Knockout achieved by CRISPR/Cas9 X = 1 bp insertion after Ile386 of the WT protein Frameshift: 100%
- Disease
- Adenocarcinoma
- Concentration
Properties
- Gene name
- ITGAE
- Gene editing type
- Knockout
- Gene editing method
- CRISPR technology
- Knockout validation
- Next Generation Sequencing
- Zygosity
- Homozygous
Quality control
- STR analysis
- CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX
Cell culture
- Biosafety level
- EU: 2 US: 2
- Adherent/suspension
- Adherent
- Gender
- Female
Handling procedures
- Initial handling guidelines
Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.
1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.- Subculture guidelines
- All seeding densities should be based on cell counts gained by established methods.
- A guide seeding density of 2x104 cells/cm2 is recommended.
- Cells should be passaged when they have achieved 80-90% confluence.
- Culture medium
- DMEM (High Glucose) + 10% FBS
- Cryopreservation medium
- Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.
Storage
- Shipped at conditions
- Dry Ice
- Appropriate short-term storage duration
- 1-2 weeks
- Appropriate short-term storage conditions
- -196°C
- Appropriate long-term storage conditions
- -196°C
Notes
We will provide viable cells that proliferate on revival.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.
Supplementary info
- This supplementary information is collated from multiple sources and compiled automatically.
- Activity summary
CD103 also known as ITGAE or integrin alpha E is a protein subunit that pairs with integrin beta 7 (ItgB7) to form a complete heterodimer known as the αEβ7 integrin complex. This protein typically weighs around 150 kDa. CD103 is mainly expressed on the surface of certain T lymphocytes such as CD8+ T cells in mucosal tissues and also in a subset of dendritic cells. Through its mechanical function CD103 mediates cell adhesion by specifically binding to E-cadherin on epithelial cells. This interaction facilitates the retention and positioning of lymphocytes in epithelial tissues.
- Biological function summary
CD103 is essential for establishing and maintaining interactions between immune cells and epithelial cells. By incorporating into the αEβ7 integrin complex it plays an important role in the localization of intraepithelial lymphocytes and dendritic cells in the gut mucosa and skin contributing to immune surveillance and protection of these barriers. CD103 helps to control lymphocyte activation and the migration process offering a critical surface marker for identifying tissue-resident memory T cells (Trm cells) and discerning their functional potential.
- Pathways
CD103 functions prominently in the immunological environment by participating in pathways that regulate lymphocyte adherence and migration. Two significant pathways it fits into include the T-cell homing and retention pathways and the antigen presentation pathway. Through these pathways CD103 interacts with molecules such as E-cadherin and impacts the movement of T cells to epithelial sites influencing tissue-specific immune responses alongside related proteins like integrin beta 7 which forms a part of the same integrin complex.
- Associated diseases and disorders
CD103 has a significant connection with inflammatory and autoimmune conditions particularly in the context of inflammatory bowel disease and certain types of cancer such as colorectal cancer. Its association with E-cadherin through the integrin complex affects cellular behavior in these diseases contributing to either barrier integrity or breakdown and abnormal immune cell infiltration. Additionally in the disease context CD103 can influence interactions with proteins that regulate immune responses and tumor surveillance highlighting its role in disease progression and therapeutic potential.
Product promise
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
1 product image
Next Generation Sequencing - Human ITGAE knockout HeLa cell line (ab274915)
1 bp insertion after Ile386 of the WT protein
Downloads
Product protocols
- Visit the general protocols
- Visit troubleshooting
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com